<DOC>
	<DOCNO>NCT00511888</DOCNO>
	<brief_summary>BACKGROUND Beta-blockers improve leave ventricular ( LV ) systolic function prognosis patient chronic heart failure . Both carvedilol nebivolol hemodynamic clinical benefit chronic heart failure ( CHF ) , unknown whether pleiotropic property may play role different subgroup patient CHF . OBJECTIVE : To compare effect nebivolol carvedilol LV function clinical outcome patient chronic heart failure reduce LV systolic function . METHODS : 160 hypertensive CHF patient , LV ejection fraction ( EF ) 40 % New York Heart Association ( NYHA ) functional class II III randomly assign receive carvedilol nebivolol therapy 24 month . At baseline 24 month treatment , patient underwent clinical evaluation : echocardiogram 6-minute walk test .</brief_summary>
	<brief_title>Nebivolol Versus Carvedilol Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>leave ventricular ejection fraction ( LVEF ) &lt; 40 % ; symptomatic heart failure functional New York Heart Association ( NYHA ) class II III ; arterial hypertension systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 85 mmHg ; clinical stability without hospital admission heart failure previous 3 month . history asthma severe chronic obstructive pulmonary disease ; severe liver kidney disease ; seconddegree third degree heart block without permanent pacemaker , sick sinus syndrome , heart rate &lt; 60 beat/min , systolic blood pressure &lt; 90 mmHg .</criteria>
	<gender>All</gender>
	<minimum_age>53 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>hypertension</keyword>
	<keyword>beta blocker</keyword>
</DOC>